Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and co… Read more
Akums Drugs and Pharmaceutical (AKUMS) - Total Liabilities
Latest total liabilities as of September 2025: ₹19.91 Billion INR
Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) has total liabilities worth ₹19.91 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Akums Drugs and Pharmaceutical - Total Liabilities Trend (2022–2025)
This chart illustrates how Akums Drugs and Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Akums Drugs and Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Akums Drugs and Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LTC Co.Ltd
KQ:170920
|
Korea | ₩153.46 Billion |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
Turkey | TL2.11 Billion |
|
Monex S.A.B. de C.V
MX:MONEXB
|
Mexico | MX$190.09 Billion |
|
Zhejiang Linuo Flow Control Techno
SHE:300838
|
China | CN¥935.96 Million |
|
Goliath Resources Limited
OTCQB:GOTRF
|
USA | $5.40 Million |
|
Anhui Tuoshan Heavy Industry Co. Ltd.
SHE:001226
|
China | CN¥444.19 Million |
|
CF Bankshares Inc
NASDAQ:CFBK
|
USA | $1.61 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Akums Drugs and Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akums Drugs and Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akums Drugs and Pharmaceutical (2022–2025)
The table below shows the annual total liabilities of Akums Drugs and Pharmaceutical from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹10.50 Billion | -62.45% |
| 2024-03-31 | ₹27.96 Billion | +9.94% |
| 2023-03-31 | ₹25.43 Billion | +4.06% |
| 2022-03-31 | ₹24.44 Billion | -- |